Anirban Maitra, M.B.B.S., an acclaimed expert in the genetics of pancreatic cancer, is the new head of pancreatic cancer research at The University of Texas MD Anderson Cancer Center.
Pancreatic cancer is the 4th leading cause of cancer-related death in the United States and has the highest mortality rate of all major cancers. 94% of pancreatic cancer patients will die within five years of diagnosis – only 6% will survive more than five years. 74% of patients die within the first year of diagnosis. Much of pancreatic research efforts have been geared towards making an earlier diagnosis possible, when the disease is not yet inoperable.
Maitra will also become co-director and scientific director of the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research on August 1, and looks forward to sharing his dedication and expertise in Houston. He was quoted as saying in a recent press release that it is the perfect time for him to join the UT MD Anderson Cancer Center because of its many progress-driven elements, from the recruitment of esteemed faculty members to its Moon Shots Program, as well as revolutionary technology now being used in both research and treatment.
According to News Medical:
Maitra also will be deputy division head for academic science in MD Anderson’s Division of Pathology and Laboratory Medicine as well as a professor in the Departments of Pathology and Translational Molecular Pathology.
“Dr. Maitra is an internationally recognized expert in pancreatic cancer,” said James Abbruzzese, M.D., director of the pancreatic research center and chair of MD Anderson’s Department of Gastrointestinal Medical Oncology.
MD Anderson President, Ronald DePinho, M.D., looks forward to having Maitra lead the center’s research endeavors on one of the most deadliest cancers. Dr. DePinho himself focuses much of his scientific work on pancreatic cancer, and just last year received the acclaimed Agilent Thought Leader Award for leading a pioneering translational research program that focuses on this disease.
Read more here.